Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

The addition of RARP to ADT significantly increased the rate of achieving radical level PSA levels (74.7% vs 38.3%; P <.001) and a shorter time to PSA nadir (2 vs 6 months; P <.001) compared with ADT ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors MEDLINE (1966-2018), Embase (1982-2018), ...

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC). This is an ASCO Meeting Abstract from the 2019 ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...